Treatment options for the advanced asymptomatic prostate cancer patient: An active immunotherapy approach

Community Oncology

Volumn 4, Issue 7, 2007, Pages 447-452

  Berger, E Roy ^a  

^a N Shore Hematol/Oncol Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DOCETAXEL; DUTASTERIDE; FINASTERIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYBRID PROTEIN; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SIPULEUCEL T; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; FEVER; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; LEUKAPHERESIS; METASTASIS; PROSTATE CANCER; PROSTATECTOMY; RIGOR; T LYMPHOCYTE; TREMOR; UNSPECIFIED SIDE EFFECT;

EID: 34547156733     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70104-8     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147-8151.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
5. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918-2925.
6. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
7. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer 2003;98:1169-1178.
8. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005;7(suppl 5):S37-S43.
9. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 2003;21:245-254.
10. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
11. Gulley J, Dahut WL. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology 2003;62(suppl 1):147-154.
12. Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc 2005;80:883-898.
13. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
14. Sternberg C. Chemotherapy in the management of prostate cancer: front line and second line therapies. Available at http://www.ascofoundation.org/ portal/site/ASCO/nuitem.64cfbd0f85cb37b2eda2be0aee37a01d/vgnextoid= 09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= vm_session_presentations_view&confID=40&sessionID=238. Accessed June 20, 2007.
15. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300-318.
16. Data on file. Dendreon Corporation, Seattle, WA.
17. Sappino AP. Screening for asymptomatic prostate cancer. Rev Med Suisse 2006;2:1326-1327, 1329-1330.
18. Cell Genesys, Inc. GVAX® immunotherapy for prostate cancer. Available at: http://www.cellgenesys.com/clinical-prostate-cancer.shtml. Accessed May 22, 2007.
19. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237.
20. Small E, Higano C, Smith, D, et al. Analysis of prognostic variables in phase II trials of GVAX vaccine for prostate cancer in metastatic hormone refractory prostate cancer. Presented at the 2006 Prostate Cancer Symposium; February 24-26, 2006; San Francisco, Calif. Abstract 254.
21. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-3094.
22. Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989;60:887-892.
23. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117:471-477.
24. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-3903.
25. Takaue Y, Tanosaki R, Tobisu K, et al. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015. Proc Am Soc Clin Oncol 2002;21:1881.
26. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107:67-74.
27. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-1463.
28. th European Cancer Conference; October 30-November 3, 2005; Paris, France. Abstract PS1
29. Buckner C. Provenge®, activated cellular immunotherapy, shows promise for treatment of androgen independent prostate cancer. Available at: http://professional.cancerconsultants.com/conference_cfs_2006.aspx?id=38679. Accessed May 22, 2007.
30. Medical News Today. Dendreon announces preliminary results from PROTECT (P-11) Study. Available at: http://www.medicalnewstoday.com/medicalnews.php? newsid=56248. Accessed May 22, 2007.
31. th Chemotherapy Foundation Symposia; November 8-11, 2006; New York, NY.